PMC8077664_01
Chest and abdomen CT was performed at diagnosis (A, E, I), after 6 months of treatment with icotinib (B, F, J), after combination treatment of icotinib and chemotherapy (C, G, K), and after anti-TB and targeted therapy (D, H, L).
cro-0014-0659-g01.jpg
PMC8077664_01_cro-0014-0659-g01.jpg
F1
Chest computed tomography (CT) revealed a tumor in the upper left lobe involving the left hilum and mediastinum (Fig. 1A, E). Moreover, multiple metastatic sites were suspected at mediastinal lymph nodes, ribs, liver, and left adrenal gland (Fig. 1I). Re-examination by radiological scans in 1-month intervals demonstrated the primary lung cancer mass had no obvious change but the remaining metastasis of the liver, adrenal gland, and mediastinal lymph nodes had decreased in size significantly (Fig. 1B, F, J). However, the pulmonary tumor remained stable after combination therapy (Fig. 1C, G). In May 2020, chest and abdomen CT demonstrated that the pulmonary mass had shrunk significantly but metastases of the liver and adrenal gland had enlarged markedly, which was assessed as disease progression (Fig. 1D, H, L).